Literature DB >> 6967702

Pulmonary injury induced by C3a and C5a anaphylatoxins.

N P Stimler, T E Hugli, C M Bloor.   

Abstract

Homogeneous anaphylatoxins C3a (human or porcine), C5a (porcine), and the porcine classic anaphylatoxin, a mixture of C5a and C5a des Arg, isolated from complement-activated serum, were shown to induce acute pulmonary injury in the guinea pig following intrabonchial instillation. The gross physiologic response to these factors is characterized by respiratory distress with rapid, shallow breathing. Administration of 8--17 micrograms/kg of porcine classic anaphylatoxin proved lethal in 50% of the animals treated. The acute response (less than 20 minutes after instillation) of pulmonary tissue to insult by the anaphylatoxins is characterized by constriction of the smooth muscle walls in both bronchioles and pulmonary arteries and by focal atelectasis. Aggregates of platelets and leukocytes in pulmonary vessels and in other organs such as the chambers of the heart were commonly observed after intrabronchial administration of the anaphylatoxins. Although C3a was never lethal in guinea pigs even when doses as high as 500 micrograms/kg were administered by the intrabronchial route, this anaphylatoxin did induce the same pattern of acute pulmonary injury as C5a. In vitro experiments employing guinea pig platelets indicated that these cells aggregate in the presence of 10(-10) M porcine C5a but are not affected by C3a (human or porcine) even at levels up to 10(-6) M. Hence, platelet aggregation as observed in vivo may be directly affected by C5a, but in the case of C3a, secondary mediators must be involved. Anaphylatoxin preparations were also shown to induce contraction of guinea pig lung strips in vitro: this effect was not inhibited by antihistamines at concentrations that blocked contraction to exogenous histamine. The in vivo response to anaphylatoxin could be blocked with high doses of the antihistamine chlorpheniramine but not by corresponding doses of diphenhydramine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967702      PMCID: PMC1903546     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Actions of anaphylatoxin on circulation and respiration of the guinea pig.

Authors:  G Bodammer; W Vogt
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

Review 2.  Diseases due to immunologic reactions in the lungs. 2.

Authors:  R P McCombs
Journal:  N Engl J Med       Date:  1972-06-08       Impact factor: 91.245

3.  Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement.

Authors:  H S Shin; R Snyderman; E Friedman; A Mellors; M M Mayer
Journal:  Science       Date:  1968-10-18       Impact factor: 47.728

4.  Acute experimental hypersensitivity pneumonitis in the guinea pig.

Authors:  H B Richerson
Journal:  J Lab Clin Med       Date:  1972-05

5.  Immunopathologic aspects of lung disease.

Authors:  J J Vazquez
Journal:  Arch Intern Med       Date:  1970-09

6.  Immunopathologic studies of an experimental model resembling Goodpasture's syndrome.

Authors:  J E Hagadorn; J J Vazquez; T R Kinney
Journal:  Am J Pathol       Date:  1969-10       Impact factor: 4.307

7.  Preparation and some properties of anaphylatoxin from hog serum.

Authors:  W Vogt
Journal:  Biochem Pharmacol       Date:  1968-05       Impact factor: 5.858

8.  The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces.

Authors:  W T Kniker; C G Cochrane
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

9.  Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.

Authors:  W D da Silva; J W Eisele; I H Lepow
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

10.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

View more
  33 in total

1.  Pathogenesis of Purtscher's retinopathy. An experimental study.

Authors:  W Behrens-Baumann; G Scheurer; H Schroer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

2.  Neutral endopeptidase-like enzyme controls the contractile activity of substance P in guinea pig lung.

Authors:  N P Stimler-Gerard
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

3.  Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin.

Authors:  Norman F Russkamp; Robert Ruemmler; Julian Roewe; Bethany B Moore; Peter A Ward; Markus Bosmann
Journal:  FASEB J       Date:  2015-05-21       Impact factor: 5.191

4.  In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.

Authors:  T Hoffmann; E C Böttger; H P Baum; M Messner; U Hadding; D Bitter-Suermann
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

5.  Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit.

Authors:  L M McManus; R N Pinckard
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

7.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 8.  Complement components as potential therapeutic targets for asthma treatment.

Authors:  Mohammad Afzal Khan; Mark R Nicolls; Besiki Surguladze; Ismail Saadoun
Journal:  Respir Med       Date:  2014-01-15       Impact factor: 3.415

9.  Site-specific mutations in the N-terminal region of human C5a that affect interactions of C5a with the neutrophil C5a receptor.

Authors:  D F Carney; T E Hugli
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

10.  Phorbol myristate acetate: in vivo effects upon neutrophils, platelets, and lung.

Authors:  J T O'Flaherty; S Cousart; A S Lineberger; E Bond; D A Bass; L R DeChatelet; E S Leake; C E McCall
Journal:  Am J Pathol       Date:  1980-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.